Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1971 1
1974 2
1976 1
1977 1
1978 3
1979 1
1984 3
1985 1
1987 2
1988 7
1989 7
1990 3
1991 6
1992 4
1993 5
1994 8
1995 8
1996 16
1997 16
1998 23
1999 25
2000 18
2001 15
2002 13
2003 23
2004 21
2005 39
2006 41
2007 36
2008 45
2009 39
2010 44
2011 56
2012 67
2013 59
2014 63
2015 65
2016 83
2017 71
2018 86
2019 75
2020 92
2021 93
2022 102
Text availability
Article attribute
Article type
Publication date

Search Results

1,250 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A, Vindeløv SD, Chen M, Harris JR, Smith M, Nicacio LV, Teng MSL, Laenen A, Rangwala R, Manso L, Mirza M, Monk BJ, Vergote I; innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators. Coleman RL, et al. Among authors: teng msl. Lancet Oncol. 2021 May;22(5):609-619. doi: 10.1016/S1470-2045(21)00056-5. Epub 2021 Apr 9. Lancet Oncol. 2021. PMID: 33845034 Clinical Trial.
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.
O'Donnell JS, Massi D, Teng MWL, Mandala M. O'Donnell JS, et al. Among authors: teng mwl. Semin Cancer Biol. 2018 Feb;48:91-103. doi: 10.1016/j.semcancer.2017.04.015. Epub 2017 May 2. Semin Cancer Biol. 2018. PMID: 28467889 Review.
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development.
Donovan KA, Ferguson FM, Bushman JW, Eleuteri NA, Bhunia D, Ryu S, Tan L, Shi K, Yue H, Liu X, Dobrovolsky D, Jiang B, Wang J, Hao M, You I, Teng M, Liang Y, Hatcher J, Li Z, Manz TD, Groendyke B, Hu W, Nam Y, Sengupta S, Cho H, Shin I, Agius MP, Ghobrial IM, Ma MW, Che J, Buhrlage SJ, Sim T, Gray NS, Fischer ES. Donovan KA, et al. Among authors: teng m. Cell. 2020 Dec 10;183(6):1714-1731.e10. doi: 10.1016/j.cell.2020.10.038. Epub 2020 Dec 3. Cell. 2020. PMID: 33275901 Free article.
Targeting immunosuppressive adenosine in cancer.
Vijayan D, Young A, Teng MWL, Smyth MJ. Vijayan D, et al. Among authors: teng mwl. Nat Rev Cancer. 2017 Dec;17(12):709-724. doi: 10.1038/nrc.2017.86. Epub 2017 Oct 23. Nat Rev Cancer. 2017. PMID: 29059149 Review.
The mutational landscape of human somatic and germline cells.
Moore L, Cagan A, Coorens THH, Neville MDC, Sanghvi R, Sanders MA, Oliver TRW, Leongamornlert D, Ellis P, Noorani A, Mitchell TJ, Butler TM, Hooks Y, Warren AY, Jorgensen M, Dawson KJ, Menzies A, O'Neill L, Latimer C, Teng M, van Boxtel R, Iacobuzio-Donahue CA, Martincorena I, Heer R, Campbell PJ, Fitzgerald RC, Stratton MR, Rahbari R. Moore L, et al. Among authors: teng m. Nature. 2021 Sep;597(7876):381-386. doi: 10.1038/s41586-021-03822-7. Epub 2021 Aug 25. Nature. 2021. PMID: 34433962
Resistance to PD1/PDL1 checkpoint inhibition.
O'Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. O'Donnell JS, et al. Among authors: teng mw. Cancer Treat Rev. 2017 Jan;52:71-81. doi: 10.1016/j.ctrv.2016.11.007. Epub 2016 Nov 27. Cancer Treat Rev. 2017. PMID: 27951441 Review.
1,250 results